# Denali Therapeutics Inc.: financial statements, quarterly

DNLI · Nasdaq · CIK 1714899 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dnli.md) · [Financials](/companies/dnli/financials.md) · [Filings](/companies/dnli/filings.md) · [Insiders](/companies/dnli/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/dnli/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.3](/filings/0001714899-24-000216.md) | [0.0 d](/filings/0001714899-26-000021.md) | [0.0](/filings/0001714899-24-000121.md) | [0.0](/filings/0001714899-24-000169.md) | [0.0](/filings/0001714899-24-000216.md) | [0.0 d](/filings/0001714899-26-000021.md) | not reported | [0.0](/filings/0001714899-26-000097.md) | not reported | not reported | not reported | [3.6](/filings/0001714899-26-000097.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001714899-26-000097.md) | not reported | not reported | not reported | [0.1](/filings/0001714899-26-000097.md) |
| Research and development | $m | [89.7](/filings/0001714899-24-000216.md) | [108 d](/filings/0001714899-26-000021.md) | [107](/filings/0001714899-25-000105.md) | [91.4](/filings/0001714899-25-000170.md) | [98.2](/filings/0001714899-25-000193.md) | [99.8 d](/filings/0001714899-26-000021.md) | [116](/filings/0001714899-26-000064.md) | [103](/filings/0001714899-26-000097.md) | [102](/filings/0001714899-25-000193.md) | [97.9 d](/filings/0001714899-26-000021.md) | [104](/filings/0001714899-26-000064.md) | [97.0](/filings/0001714899-26-000097.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [32.3](/filings/0001714899-26-000097.md) | not reported | not reported | not reported | [36.3](/filings/0001714899-26-000097.md) |
| Operating income | $m | [(114)](/filings/0001714899-24-000216.md) | [(133) d](/filings/0001714899-26-000021.md) | [(118)](/filings/0001714899-25-000105.md) | [(117)](/filings/0001714899-25-000170.md) | [(123)](/filings/0001714899-25-000193.md) | [(130) d](/filings/0001714899-26-000021.md) | [(146)](/filings/0001714899-26-000064.md) | [(135)](/filings/0001714899-26-000097.md) | [(137)](/filings/0001714899-25-000193.md) | [(137) d](/filings/0001714899-26-000021.md) | [(137)](/filings/0001714899-26-000064.md) | [(131)](/filings/0001714899-26-000097.md) |
| Income tax | $m | [0.0](/filings/0001714899-23-000146.md) | [0.0 d](/filings/0001714899-26-000021.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(99.4)](/filings/0001714899-24-000216.md) | [(119) d](/filings/0001714899-26-000021.md) | [(102)](/filings/0001714899-25-000105.md) | [(99.0)](/filings/0001714899-25-000170.md) | [(107)](/filings/0001714899-25-000193.md) | [(115) d](/filings/0001714899-26-000021.md) | [(133)](/filings/0001714899-26-000064.md) | [(124)](/filings/0001714899-26-000097.md) | [(127)](/filings/0001714899-25-000193.md) | [(129) d](/filings/0001714899-26-000021.md) | [(128)](/filings/0001714899-26-000064.md) | [(128)](/filings/0001714899-26-000097.md) |
| Diluted EPS | $ per share | [(0.72)](/filings/0001714899-24-000216.md) | not reported | [(0.68)](/filings/0001714899-25-000105.md) | [(0.59)](/filings/0001714899-25-000170.md) | [(0.63)](/filings/0001714899-25-000193.md) | not reported | [(0.78)](/filings/0001714899-26-000064.md) | [(0.72)](/filings/0001714899-26-000097.md) | [(0.74)](/filings/0001714899-25-000193.md) | not reported | [(0.69)](/filings/0001714899-26-000064.md) | [(0.68)](/filings/0001714899-26-000097.md) |
| Basic EPS | $ per share | [(0.72)](/filings/0001714899-24-000216.md) | not reported | [(0.68)](/filings/0001714899-25-000105.md) | [(0.59)](/filings/0001714899-25-000170.md) | [(0.63)](/filings/0001714899-25-000193.md) | not reported | [(0.78)](/filings/0001714899-26-000064.md) | [(0.72)](/filings/0001714899-26-000097.md) | [(0.74)](/filings/0001714899-25-000193.md) | not reported | [(0.69)](/filings/0001714899-26-000064.md) | [(0.68)](/filings/0001714899-26-000097.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [148](/filings/0001714899-23-000146.md) | [127](/filings/0001714899-25-000066.md) | [60.6](/filings/0001714899-24-000121.md) | [74.7](/filings/0001714899-24-000169.md) | [90.6](/filings/0001714899-24-000216.md) | [175](/filings/0001714899-26-000021.md) | [56.9](/filings/0001714899-25-000105.md) | [141](/filings/0001714899-25-000170.md) | [91.0](/filings/0001714899-25-000193.md) | [205](/filings/0001714899-26-000097.md) | [388](/filings/0001714899-26-000064.md) | [202](/filings/0001714899-26-000097.md) |
| Current assets | $m | [1,143](/filings/0001714899-23-000146.md) | [1,064](/filings/0001714899-25-000066.md) | [974](/filings/0001714899-24-000121.md) | [928](/filings/0001714899-24-000169.md) | [869](/filings/0001714899-24-000216.md) | [864](/filings/0001714899-26-000021.md) | [879](/filings/0001714899-25-000105.md) | [935](/filings/0001714899-25-000170.md) | [883](/filings/0001714899-25-000193.md) | [901](/filings/0001714899-26-000097.md) | [1,023](/filings/0001714899-26-000064.md) | [754](/filings/0001714899-26-000097.md) |
| Total assets | $m | [1,237](/filings/0001714899-23-000146.md) | [1,154](/filings/0001714899-25-000066.md) | [1,581](/filings/0001714899-24-000121.md) | [1,503](/filings/0001714899-24-000169.md) | [1,454](/filings/0001714899-24-000216.md) | [1,374](/filings/0001714899-26-000021.md) | [1,271](/filings/0001714899-25-000105.md) | [1,166](/filings/0001714899-25-000170.md) | [1,056](/filings/0001714899-25-000193.md) | [1,145](/filings/0001714899-26-000097.md) | [1,266](/filings/0001714899-26-000064.md) | [1,158](/filings/0001714899-26-000097.md) |
| Current liabilities | $m | [71.2](/filings/0001714899-23-000146.md) | [78.0](/filings/0001714899-25-000066.md) | [82.6](/filings/0001714899-24-000121.md) | [74.5](/filings/0001714899-24-000169.md) | [87.1](/filings/0001714899-24-000216.md) | [102](/filings/0001714899-26-000021.md) | [91.9](/filings/0001714899-25-000105.md) | [91.1](/filings/0001714899-25-000170.md) | [90.1](/filings/0001714899-25-000193.md) | [98.4](/filings/0001714899-26-000097.md) | [110](/filings/0001714899-26-000064.md) | [90.1](/filings/0001714899-26-000097.md) |
| Total liabilities | $m | [118](/filings/0001714899-23-000146.md) | [123](/filings/0001714899-25-000066.md) | [126](/filings/0001714899-24-000121.md) | [116](/filings/0001714899-24-000169.md) | [136](/filings/0001714899-24-000216.md) | [144](/filings/0001714899-26-000021.md) | [149](/filings/0001714899-25-000105.md) | [139](/filings/0001714899-25-000170.md) | [129](/filings/0001714899-25-000193.md) | [131](/filings/0001714899-26-000097.md) | [340](/filings/0001714899-26-000064.md) | [323](/filings/0001714899-26-000097.md) |
| Shareholders' equity | $m | [1,118](/filings/0001714899-24-000216.md) | [1,031](/filings/0001714899-26-000021.md) | [1,455](/filings/0001714899-25-000170.md) | [1,387](/filings/0001714899-25-000193.md) | [1,318](/filings/0001714899-25-000193.md) | [1,230](/filings/0001714899-26-000097.md) | [1,123](/filings/0001714899-26-000097.md) | [1,027](/filings/0001714899-26-000097.md) | [926](/filings/0001714899-25-000193.md) | [1,014](/filings/0001714899-26-000097.md) | [926](/filings/0001714899-26-000097.md) | [835](/filings/0001714899-26-000097.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(87.4) d](/filings/0001714899-24-000216.md) | [(98.7) d](/filings/0001714899-26-000021.md) | [(114)](/filings/0001714899-25-000105.md) | [(91.2) d](/filings/0001714899-25-000170.md) | [(59.1) d](/filings/0001714899-25-000193.md) | [(83.7) d](/filings/0001714899-26-000021.md) | [(131)](/filings/0001714899-26-000064.md) | [(75.3) d](/filings/0001714899-26-000097.md) | [(107) d](/filings/0001714899-25-000193.md) | [(98.5) d](/filings/0001714899-26-000021.md) | [(131)](/filings/0001714899-26-000064.md) | [(97.0) d](/filings/0001714899-26-000097.md) |
| Capital expenditure | $m | [2.1 d](/filings/0001714899-24-000216.md) | [2.2 d](/filings/0001714899-26-000021.md) | [2.2](/filings/0001714899-25-000105.md) | [4.8 d](/filings/0001714899-25-000170.md) | [3.9 d](/filings/0001714899-25-000193.md) | [5.1 d](/filings/0001714899-26-000021.md) | [5.1](/filings/0001714899-26-000064.md) | [4.3 d](/filings/0001714899-26-000097.md) | [(1.4) d](/filings/0001714899-25-000193.md) | [1.5 d](/filings/0001714899-26-000021.md) | [2.5](/filings/0001714899-26-000064.md) | [0.8 d](/filings/0001714899-26-000097.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [123](/filings/0001714899-23-000146.md) | [137](/filings/0001714899-24-000121.md) | [141](/filings/0001714899-24-000169.md) | [138](/filings/0001714899-24-000216.md) | [149](/filings/0001714899-25-000105.md) | [169](/filings/0001714899-25-000170.md) | [169](/filings/0001714899-25-000193.md) | [171](/filings/0001714899-26-000064.md) | [171](/filings/0001714899-26-000097.md) | [172](/filings/0001714899-25-000193.md) | [187](/filings/0001714899-26-000064.md) | [187](/filings/0001714899-26-000097.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 159,847,403 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001714899-26-000097.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.